61.12 0.00 (0.00%)
After hours: 5:14PM EDT
|Bid||61.35 x 800|
|Ask||61.58 x 1200|
|Day's Range||60.56 - 61.95|
|52 Week Range||42.08 - 89.05|
|Beta (3Y Monthly)||1.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 25, 2017 - Oct 30, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||82.11|
HENDERSONVILLE, TN / ACCESSWIRE / August 19, 2019 / The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 18 years, announces that an investor of Teladoc ...
Teladoc's (TDOC) vast business presence in the growing telehealth industry with many deal wins and international expansion should drive long-term growth.
In this article we are going to estimate the intrinsic value of Teladoc Health, Inc. (NYSE:TDOC) by projecting its...
PURCHASE, NY, Aug. 06, 2019 -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that Jason Gorevic, chief executive officer, and Mala.
Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Teladoc Health (TDOC) has filed a shareholder derivative complaint against the company's officers and directors for breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and violations of the Securities Exchange Act of 1934 between March 3, 2016 and the present. Teladoc Health is a virtual care solution company that connects people with medical practitioners. If you suffered a loss as a result of Teladoc's misconduct, click here.
Teladoc (TDOC) delivered earnings and revenue surprises of -2.50% and 0.46%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Year-over-year Q2 revenue grows 38% to $130.3 million and total visits increase 70% to 908,000 Year-over-year first half revenue grows 41% to $258.8 million and total visits.
NEW YORK, NY / ACCESSWIRE / July 31, 2019 / Teladoc Health, Inc. (TSX: TDOC ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 31, 2019 at 4:30 PM Eastern ...
Teladoc Health (TDOC), the global leader in virtual care, announced that it has named David Sides as chief operating officer. A former corporate CEO and a longtime Cerner Corporation executive, Sides brings an impressive track record within the health tech sector to oversee the company’s worldwide commercial, technology and operations teams. “As we continue to grow and diversify our global footprint, David’s proven ability to scale businesses across markets will be instrumental in our continued success,” said Jason Gorevic, CEO, Teladoc Health.
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Teladoc, Inc. (TDOC). According to a complaint filed on December 12, 2018, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies.
Stocks are sitting atop the clouds. All three major indexes have recently surged to surged to all-time highs amid strong signals that the Federal Reserve will cut interest rates soon. Standard & Poor's 500-stock index just closed above 3,000 for the first time. The Dow Jones Industrial Average recently made its first finish above the 27,000 mark.But the question of whether the markets can maintain these lofty heights is something you should seriously consider when making stock picks over the next few weeks.Consider this: More than three-quarters of S&P; 500 companies have issued negative earnings per share (EPS) guidance for the second quarter thanks to trade uncertainty and lingering concerns about global growth. (Those earnings reports will be rolling out over the next couple months.) And while Wall Street is absolutely pricing in an interest-rate cut, no one yet knows for sure whether the Fed will cut, and how deeply it will cut if it does.So tread carefully in the second half. The key is to find stocks that are not just primed to continue outperforming, but also less vulnerable to slumping along with a broader-market pullback. One way to do this is to seek out stocks with a strong Street sentiment. TipRanks tracks more than 5,200 analysts and compiles their ratings to deliver a picture of just how optimistic (or pessimistic) the pros are about most companies you can invest in.These are the seven top stock picks for the second half, according to analyst ratings doled out over the past three months. SEE ALSO: 25 Stocks Every Retiree Should Own
PURCHASE, NY, July 12, 2019 -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that it will release second-quarter 2019 results on.
WOONSOCKET, R.I., July 10, 2019 /PRNewswire/ -- CVS Health (CVS) today announced that MinuteClinic, the company's retail medical clinic, has rolled out its virtual visit offering in eight additional states. People with minor illnesses and injuries, skin conditions and other wellness needs can now seek care through MinuteClinic Video Visits, a telehealth offering, in the states of Arkansas, Connecticut, Hawaii, Indiana, Minnesota, Missouri, Oklahoma and Texas. MinuteClinic Video Visits provide patients with access to care 24 hours a day, seven days a week from their mobile device or computer.
2019 has been a rocky year for the healthcare industry. The general healthcare market sell-off combined with criticism over high costs poses a cause for concern. Despite the lackluster performance of many healthcare stocks so far in 2019, there are a few standouts with long-term growth potential. Using data from TipRanks, we’ve narrowed down three stocks in the healthcare space that analysts believe are well positioned for future growth. Boston Scientific Corporation (BSX)Unlike other stocks in the healthcare industry, Boston Scientific shares saw significant growth over the last year. The medical equipment manufacturer’s stock increased 22.5% while the industry as a whole saw only a 4% increase. In the quarter ending March 31, the company reported calendar year increases in revenue and net profit. Revenue was up from $2.38 billion to $2.49 billion while net profit increased from $298 million to $424 million.Boston Scientific’s long-term growth plan, which includes projections of double digit adjusted EPS growth through 2020, gives analysts reason to believe the company will continue to outperform. Raj Denhoy, a top analyst from Jeffries, raised his price target from $44 to $48 stating that the company’s projections from their investor meeting were “another positive look at a story that has been in sharp ascendancy for the last five years.” He added that the projections are even somewhat conservative given the company’s stability and the addition of new products in the next few quarters. Another five-star analyst, Matt Miksi of Credit Suisse, explained that he is unsurprised by Boston’s success when discussing the company’s sale of various products from their portfolio to Varian for $90 million. He maintained the stock’s Outperform rating and $45.00 price target, indicating a 5.56% upside. The Street’s outlook on the stock is bullish, with 10 analysts from TipRanks giving a buy rating vs just 1 hold over the last three months. The stock boasts a ‘Strong Buy’ analyst consensus and an average price target of $45.63, suggesting a 7.04% upside. View BSX Price Target & Analyst Rating Details Invitae Corporation (NVTA)Invitae is an innovative biotech company in the genetic testing segment of the market whose goal is to make genetic screenings more affordable and accessible. Five-star financial blogger, Todd Campbell, notes that the company cut the cost of goods sold by upwards of 20% over the last year as well as reported year-over-year sales of $148 million, a 117% increase. Management is projecting sales of $220 million in 2019 and a test volume of 500,000. Additionally, the company announced on June 17 that they are set to acquire Singular Bio. “The acquisition of Singular Bio gives Invitae a critical technology that can turn the NIPS business into a 50% gross margin performer once fully integrated into the firm’s process, and if you broke out Invitae's cancer business, it turned a profit as a standalone business as of Q1 of this year,” stated Sean George, the company’s CEO. Five-star rated Cowen & Co. analyst, Doug Schenkel, is confident in the stocks ability to grow, reiterating his Outperform rating and $30.00 price target. He believes Singular Bio’s “flexible, quick, and less expensive technology will give Invitae a competitive advantage over other companies with sequencing-based and microarray-based approaches for some applications including NIPS/NIPT.”The consensus among analysts is that the stock is a ‘Strong Buy’, with an average price target of $30.00, suggesting a 23.61% upside. View NVTA Price Target & Analyst Rating Details Teladoc Health, Inc. (TDOC)The last stock on our list doesn’t appear to be slowing down any time soon. Teladoc meets the growing demand for healthcare access in a cost-effective way by providing virtual medical care through telephone and videoconferencing technology. Share prices surged by 35.73% year-to-date. Management is confident that this growth will continue throughout the rest of the year. Based on Teladoc’s recent acquisitions as well as their competitive advantage within this segment of the healthcare sector, management is anticipating 37% revenue growth. In the most recent quarter, the company reported 29% organic growth with 1,063,000 total visits. Richard Close, an analyst at Canaccord Genuity, believes that the telemedicine company’s “penetration into its existing client base will allow it to generate robust organic growth.” He maintains his buy rating on the stock and price target of $95.00 (41.20% upside). Five-star Piper Jaffray analyst, Sean Wieland, remains bullish on the stock. He explained that he views the completion of their CFO search and an impending United deal as “two important catalysts and remains a buyer of the stock in front of them.” He reiterated his Overweight rating and price target of $86.00, suggesting a 27.82% upside.While the on-demand remote medical care provider isn’t profitable yet, analysts believe in Teladoc’s growth potential. The stock has a ‘Strong Buy’ analyst consensus, with 12 out of 13 analysts on TipRanks giving a buy rating. The average price target of $79.83 shows that analysts believe the stock price could increase by 18.65%. View TDOC Price Target & Analyst Rating DetailsFind your own best investment with TipRanks’ Analysts’ Top Stocks page.